These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 122298)

  • 1. Aldose reductase inhibition: studies with alrestatin.
    Gabbay KH; Spack N; Loo S; Hirsch HJ; Ackil AA
    Metabolism; 1979 Apr; 28(4 Suppl 1):471-6. PubMed ID: 122298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
    Fagius J; Jameson S
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
    Handelsman DJ; Turtle JR
    Diabetes; 1981 Jun; 30(6):459-64. PubMed ID: 6785131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report.
    Culebras A; Alió J; Herrera JL; López-Fraile MI
    Arch Neurol; 1981 Feb; 38(2):133-4. PubMed ID: 6781454
    [No Abstract]   [Full Text] [Related]  

  • 5. Human placenta aldose reductase. Forms sensitive and insensitive to inhibition by alrestatin.
    Maragoudakis ME; Wasvary J; Hankin H; Gargiulo P
    Mol Pharmacol; 1984 May; 25(3):425-30. PubMed ID: 6427599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil.
    O'Brien MM; Schofield PJ; Edwards MR
    J Neurochem; 1982 Sep; 39(3):810-4. PubMed ID: 6808090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB; Herold K; Bartkus C
    Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
    Greene DA; Lattimer SA
    Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB; Towle VL; Maselli R; Herold K
    Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 13. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
    Jaspan J
    Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
    Bhatnagar A; Liu SQ; Das B; Ansari NH; Srivastava SK
    Biochem Pharmacol; 1990 Mar; 39(6):1115-24. PubMed ID: 2157439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
    Jaspan J; Maselli R; Herold K; Bartkus C
    Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.